NEWARK, Del., Feb. 4, 2026 /PRNewswire/ — The global food allergy market is estimated at USD 44.1 billion in 2025 and is projected to reach USD 73.2 billion by 2035, expanding at a 5.2% CAGR over the forecast period, according to the latest Report by Future Market Insights (FMI). The outlook reflects rising prevalence of allergic conditions, growing awareness of food-related anaphylaxis, and improving diagnostic capabilities—alongside stronger regulatory emphasis on allergen labeling and safer food environments.
The market includes solutions used across food allergy diagnosis, symptom management, emergency response, and emerging desensitization approaches, with hospitals and specialty clinics strengthening protocols for severe reactions and complex cases. Growth is also supported by increased research investment and the gradual integration of food allergy management into broader primary-care pathways.
Key takeaways (2025–2035)
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075 For Sales – [email protected] For Media – [email protected] For web – https://www.futuremarketinsights.com/ Logo – https://mma.prnewswire.com/media/1197648/3531122/FMI_Logo.jpg SOURCE Future Market Insights, Inc.
- Market size (2025): USD 44.1B
- Forecast (2035): USD 73.2B
- CAGR (2025–2035): 5.2%
- Leading allergen source (2025): Peanut (30.5%)
- Leading treatment (2025): Antihistamines (35.0%)
- Leading end-use (2025): Hospitals (42.0%)
- Key growth regions: North America, Asia-Pacific, Europe
- Rising prevalence and higher-risk co-morbidities
Food allergies commonly coexist with asthma, and increased asthma incidence through 2025–2035 is expected to raise the risk of severe symptoms in certain patient groups—supporting demand for both preventive and therapeutic measures. - Regulatory and industry compliance around allergens
Regulatory emphasis on allergen labeling and heightened awareness across food manufacturing and foodservice settings are increasing the need for accurate detection, standardized management practices, and patient education. - Expanding R&D and treatment innovation
Advances in immunotherapy techniques and broader research into immune tolerance mechanisms are widening the pipeline of approaches beyond symptomatic relief. This includes ongoing work in immunomodulation strategies such as peptide immunotherapy, allergy DNA vaccination, immunostimulatory DNA vaccination, and anti-IgE approaches.
- North America: Forecast to account for 43% of global food allergy treatments, supported by a large patient base, high awareness, and ongoing drug development activity in the U.S. market, including oral immunotherapy availability for peanut allergy patients under certain suitability criteria.
- Europe: Expected to contribute 36% of worldwide revenue, reflecting a significant allergy-affected population and continued growth in allergen testing and compliance needs.
- underdiagnosis due to limited awareness in some settings
- lack of uniform diagnostic criteria affecting prevalence estimates and management standardization
- inaccurate test results or delays in reporting
- practical limitations for pediatric testing (including blood volume needs for multiple tests)
- high testing costs and uneven availability of allergy testing in certain regions
- Allergen source: peanut, gluten, mustard, milk, egg, fish, others
- Treatment: antihistamines, adrenaline, oral immunotherapy, others
- End use: hospitals, clinics, ambulatory surgery centers
- Regions: North America, Latin America, Europe, Asia Pacific, Middle East & Africa
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075 For Sales – [email protected] For Media – [email protected] For web – https://www.futuremarketinsights.com/ Logo – https://mma.prnewswire.com/media/1197648/3531122/FMI_Logo.jpg SOURCE Future Market Insights, Inc.

Source link















Leave a Reply